HL 02

Drug Profile

HL 02

Alternative Names: HL02

Latest Information Update: 19 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hualan Genetic Engineering
  • Class Antineoplastics
  • Mechanism of Action ERBB 2 receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 16 Aug 2017 Preclinical trials in Breast cancer in China, before August 2017 (ChiCTR-RIC17012372)
  • 16 Aug 2017 First Hospital of Jilin University and Hualan Genetic Engineering plans a phase I trial for Breast cancer (In volunteers) in China in September 2017 (ChiCTR-RIC17012372)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top